Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where S. Le Guellec is active.

Publication


Featured researches published by S. Le Guellec.


Annals of Oncology | 2018

Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas

S. Le Guellec; Tom Lesluyes; E Sarot; C Valle; Thomas Filleron; Philippe Rochaix; Thibaud Valentin; G. Perot; Jean-Michel Coindre; Frédéric Chibon

Background Prediction of metastatic outcome in sarcomas is challenging for clinical management since they are aggressive and carry a high metastatic risk. A 67-gene expression signature, the Complexity INdex in SARComas (CINSARC), has been identified as a better prognostic factor than the reference pathological grade. Since it cannot be applied easily in standard laboratory practice, we assessed its prognostic value using nanoString on formalin-fixed, paraffin-embedded (FFPE) blocks to evaluate its potential in clinical routine practice and guided therapeutic management. Methods A code set consisting of 67 probes derived from the 67 genes of the CINSARC signature was built and named NanoCind®. To compare the performance of RNA-seq and nanoString (NanoCind®), we used expressions of various sarcomas (n = 124, frozen samples) using both techniques and compared predictive values based on CINSARC risk groups and clinical annotations. We also used nanoString on FFPE blocks (n = 67) and matching frozen and FFPE samples (n = 45) to compare their level of agreement. Metastasis-free survival and agreement values in classification groups were evaluated. Results CINSARC strongly predicted metastatic outcome using nanoString on frozen samples (HR = 2.9, 95% CI: 1.23-6.82) with similar risk-group classifications (86%). While more than 50% of FFPE blocks were not analyzable by RNA-seq owing to poor RNA quality, all samples were analyzable with nanoString. When similar (risk-group) classifications were measured with frozen tumors (RNA-seq) compared with FFPE blocks (84% agreement), the CINSARC signature was still a predictive factor of metastatic outcome with nanoString on FFPE samples (HR = 4.43, 95% CI: 1.25-15.72). Conclusion CINSARC is a material-independent prognostic signature for metastatic outcome in sarcomas and outperforms histological grade. Unlike RNA-seq, nanoString is not influenced by the poor quality of RNA extracted from FFPE blocks. The CINSARC signature can potentially be used in combination with nanoString (NanoCind®) in routine clinical practice on FFPE blocks to predict metastatic outcome.


Revue Des Maladies Respiratoires | 2007

097 In vitro performances of an innovative device for mesh nebulizer

Laurent Vecellio; P. Diot; S. Le Guellec; Gilles Chantrel

⇒ Inhalable fraction was measured by a filtering method. A breath simulator (Harvard Apparatus) was setup in accordance with the European Standard (500ml, 1/1, 15/min). Aerosol was collected on absolute filters placed at the mouthpiece (inhaled mass) (Figure 3). Inhaled mass was calculated by the residual gravimetric method (1) which weighs the filters both before and after aerosol collection and filter drying corrected by the proportion of drug contained in total mass. Inhaled volume was calculated by the ratio between inhaled mass and the drug concentration.


Revue Des Maladies Respiratoires | 2007

096 In vitro/In vivo performances of the Idehaler® holding chamber operating with Aeroneb® Pro

Laurent Vecellio; L. Colombier; P. Diot; S. Le Guellec; Gilles Chantrel

Continuous nebulization generates a loss of drug into the air. This loss is due to aerosol leaks and exhaled aerosol. Aerosol leak is defined by the aerosol produced by the nebulizer during patient exhalation phase. Aerosol is produced out of the nebulizer in the ambient air or on a filter. Idehaler with Aeroneb Pro limits the aerosol leak (Fig.1). Exhaled aerosol is defined by the aerosol that goes out of patient airways. During the patient inhalation, aerosol penetrates into the patient airways; and at the end of the inhalation, all aerosol is not deposited into the patient. A part of inhaled aerosol (not deposited aerosol) goes out of the patient during the next exhalation phase. To limit exhaled aerosol, some nebulizers generate the aerosol only during the first part of patient inhalation. A consequence of this system is an increasing of nebulization time. To increase Idehaler efficiency by decreasing aerosol leak and exhaled aerosol with a lower increasing nebulization time, a new nebulization system based on the interruption of the aerosol production during the patient inhalation phase has been developed (Patent pending). The idea of this system is to nebulize an aerosol in a chamber during the patient exhalation and to stop the nebulization during the patient inhalation. In vitro/In vivo performances of the Idehaler® holding chamber operating with Aeroneb® Pro L. Vecellio1, L. Colombier1, P. Diot1, S. Le Guellec2, G. Chantrel2


Revue Des Maladies Respiratoires | 2005

074 PAPRICA Pollution Aérienne et Pathologie Respiratoire : Impact de la Communication sur l’Air

S. Lacour; N. Veron; S. Le Guellec; J. Brocca; M. De Monte; P.H. Deprez; P. Dior; Valérie Leblond

Introduction Gaz oxydant puissant, l’ozone est l’un des principaux polluants de l’air. La loi sur l’air de 1996 definit le seuil d’information du public a 180 μg/m 3 /h. Cependant, plusieurs etudes ont montre que l’ozone a des effets nocifs sur la sante des personnes fragiles sur le plan respiratoire a partir d’une concentration de 110 μg/m 3 prolongee au moins 8 heures. Le reseau PAPRICA regroupe differents partenaires de la region Centre concernes par la pollution atmospherique et son impact sur la sante. Il est destine a tester l’hypothese qu’une information anticipee des depassements du seuil de 110 μg/m 3 /8h d’ozone dans l’air pourrait etre benefique a la sante de personnes atteintes d’insuffisance respiratoire chronique (IRC). Methodes L’etude s’est deroulee au cours de l’ete 2003. Un systeme de prevision des depassements du seuil de 110 μg/m 3 /8h d’ozone dans l’air a ete mis en place en Region Centre. Nous avons constitue 2 groupes comparables de patients en terme de pathologie (IRC obstructive et restrictive) et d’appareillage (O 2 ≤2 1/min, O 2 > 2 1/min, nebuliseur). Lors de la prevision d’un depassement du seuil de 110 μg/m 3 /8h d’ozone dans l’air pour le jour suivant, un message d’alerte a ete envoye a la moitie des patients (groupe 1, 56 patients). Le groupe 2 (temoin, 56 patients) n’a pas recu cette information. Une analyse comparative de la consommation medicale (consommation de medicaments de l’appareil respiratoire, de corticoides et d’antibiotiques, consultations aupres de professionnels de sante et admissions hospitalieres), de l’etat de sante global (questionnaire journalier simple) et de la qualite de vie (questionnaire respiratoire du Saint Georges Hospital) a ete realisee entre les patients des 2 groupes. Resultats Les patients informes (groupe 1) ont eu moins de symptomes respiratoires, ont moins consomme de medicaments et d’oxygene et ont moins fait appel aux professionnels de sante que les patients non informes (groupe 2). D’autre part, les analyses realisees sur le cout global de la consommation medicale indiquent que la somme des soins rembourses est moins elevee pour les patients informes. Conclusion Les patients ont une meilleure perception de leur etat de sante et de leur qualite de vie ainsi qu’une consommation de soins moins importante lorsqu’ils ont ete informes a l’avance des depassements du seuil de 110 μg/m 3 /8h d’ozone dans l’air.


Revue Des Maladies Respiratoires | 2005

057 Aérosolisation et contrôle qualité du dépôt pulmonaire par imagerie radioisotopique: une nouvelle modalité d’administration intratrachéale chez le rat

S. Le Guellec; J. Montharu; A. Elmoujahed; M. De Monte

Introduction Au sein de l’Unite INSERM 618, le laboratoire « aerosols et cancer bronchopulmonaire » s’interesse au ciblage pulmonaire par le developpement de nouveaux traceurs cellulaires, de nouvelles methodologies d’administration (voie aerosol) et d’exploration scintigraphique dans les modeles animaux. C’est dans cette optique que nous avons defini et developpe un protocole d’administration intratracheale chez le rat. Nous proposons d’exposer cette methode novatrice alliant la technique d’aerosolisation a l’imagerie radioisotopique. Methodes La technique consiste (i) a generer l’aerosol d’un compose radiomarque (compose-Tc99m) ou radiotrace (compose + traceur-Tc99m) directement sur les poumons de l’animal anesthesie; (ii) a controler l’administration pulmonaire en realisant une acquisition scintigraphique a laide d’une mini-gamma camera dediee a l’imagerie du petit animal. Resultats L’etape d’aerosolisation est optimisee par l’utilisation d’un Microsprayer ® (PennCentury) generant un aerosol de 30 a 35 μm. Celui-ci est reparti dans les poumons de facon tres homogene offrant une large surface de contact avec l’endothelium pulmonaire et evitant une distribution eparse du compose comme obtenue avec une instillation. La position et l’anesthesie de l’animal ont ete egalement optimisees. L’enregistrement d’un fichier image du depot pulmonaire offre des avantages qualitatifs et quantitatifs: controle et caracterisation du depot (selectif, homogene), quantification du depot pulmonaire selon differentes zones. Conclusions Cette technique permet l’obtention d’un modele d’administration proche du modele par inhalation naturelle en cage d’exposition ; beneficiant en plus de la maitrise de la dose administree de la quantification du depot pulmonaire et du temps d’experimentation raccourci (aerosolisation d’un animal = 30 secondes).


Annals of Oncology | 2014

Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study

S. Mathoulin-Pélissier; C. Chevreau; C. Bellera; E. Bauvin; M. Savès; P. Grosclaude; S. Albert; J. Goddard; S. Le Guellec; M. Delannes; Binh Bui; Jean Mendiboure; E. Stoeckle; J.-M. Coindre; G. Kantor; M. Kind; A. Cowppli-Bony; S. Hoppe; Antoine Italiano


publisher | None

title

author


Annals of Oncology | 2018

Chemotherapy in localized Soft Tissue Sarcoma: will we soon have to treat grade 1 tumours? Update on CINSARC performances

Thibaud Valentin; Tom Lesluyes; S. Le Guellec; Frédéric Chibon


Annals of Oncology | 2017

1478PDAdult Translocation-related soft tissue sarcomas (TRS): Presentation, management and outcome of 2,143 cases confirmed by expert pathologists

Nicolas Penel; J.-M. Coindre; Antoine Giraud; P. Terrier; D. Ranchere-Vince; Françoise Collin; S. Le Guellec; C. Bazille; Marick Laë; G. De Pinieux; Isabelle Ray-Coquard; S. Bonvalot; A. Le Cesne; Y-M. Robin; E. Stoeckle; Françoise Ducimetière; Maud Toulmonde; J-Y. Blay


Orthopaedic Proceedings | 2012

GALECTIN-1 IS A POWERFUL MARKER TO DISTINGUISH CHONDROBLASTIC OSTEOSARCOMA AND CONVENTIONAL CHONDROSARCOMA

Anne Gomez-Brouchet; Frédéric Mourcin; P.A. Gourault; Corinne Bouvier; G. De Pinieux; S. Le Guellec; Pierre Brousset; Marie-Bernadette Delisle; Claudine Schiff

Collaboration


Dive into the S. Le Guellec's collaboration.

Top Co-Authors

Avatar

P. Diot

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar

Laurent Vecellio

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

E. Stoeckle

Argonne National Laboratory

View shared research outputs
Top Co-Authors

Avatar

J.-M. Coindre

Argonne National Laboratory

View shared research outputs
Top Co-Authors

Avatar

A. Le Cesne

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

C. Chevreau

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Emmanuelle Mercier

François Rabelais University

View shared research outputs
Researchain Logo
Decentralizing Knowledge